Vivek Ra­maswamy bags op­tion rights on Dai­ichi’s pipeline drugs; Achillion drops a lead pro­gram; Zio­pharm cre­ates new de­vel­op­ment com­pa­ny for Chi­na

→ No longer con­tent to pick off 1 drug at a time for his grow­ing sta­ble of com­pa­nies, Roivant chief Vivek Ra­maswamy has struck a deal that gives him op­tions on a slate of pro­grams in de­vel­op­ment at Dai­ichi Sankyo. And he can use these new drugs to seed the pipelines of his fu­ture star­tups.

→ At a time high in­sulin prices have be­come a light­ning rod is­sue in the US, No­var­tis is team­ing up with Chi­na’s Gan & Lee to pro­vide cheap­er knock­offs of three big brands.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER